临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
prognostic biomarker validation,259–261 261
study design inclusion,330 330
surrogate marker criteria,331 331
thymidine phosphorylase as survival biomarker,248–249 249
Biostatistics comparison analysis,175–176 176
hazard ratio calculation,171–172 172
Kaplan-Meier plot censoring data,168–169,172 172
time of enrollment and data,172–174 174
one-tailed test,176–177 177
P-value calculation,166,168,180–186 186
hypothesis testing,177–180 180
superiority analysis versus non-inferiority analysis,187–190 190
two-tailed test,176–177 177
Black box warning,565–567 567
Decision aid informed consent,556–558 558
Decision tree Baselga schema,31 31
Demetri study,203–206 206
Dendritic cell (DC)classification,487–488 488
ABC transporters,76–78 78
AC see Active control Active control (AC),24,27,44–46 46
Active placebo,133–134 134
Acute lymphocytic leukemia (ALL)clinical features,284–287 287
cytogenetics for diagnosis and prediction,300–304,323 323